DLL4 and pancreatic neoplasm: Treatment with either human or mouse anti-Dll4 delayed pancreatic tumor recurrence following termination of gemcitabine treatment, and the two together produced an additive effect, suggesting a novel therapeutic approach for pancreatic cancer treatment through antagonism of DLL4/Notch signaling [36].